PURPOSE To evaluate the effect of systemic cyclosporine (CsA) on ocular disease in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) patients. METHODS In this retrospective, comparative cohort study at a single center, patients with a diagnosis of SJS/TEN and with at least 3 months of follow up were divided into two groups: those who received systemic CsA and those who did not receive systemic CsA. Best-corrected visual acuity (BCVA) and chronic ocular surface complications score (COCS) at final follow-up were compared between the two groups. RESULTS The median age and follow-up period of patients was 29 years (range, 1.5-71 years) and 16.8 months (range, 3.67-91.58 months), respectively. BCVA, COCS, meibomian gland dysfunction, limbal stem cell deficiency, and the need for mucous membrane grafting and scleral lenses were not significantly different between patients who received systemic CsA as compared to patients who did not receive systemic CsA. CONCLUSIONS In this small cohort of patients with SJS/TEN, we could identify no association between the use of systemic CsA as a component of their initial therapy and chronic ocular complications.

中文翻译：

---

全身环孢素在急性史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症中对眼部疾病的影响。


目的 评估全身环孢素 (CsA) 对 Stevens-Johnson 综合征 (SJS) 和中毒性表皮坏死松解症 (TEN) 患者眼部疾病的影响。方法 在这项单中心回顾性比较队列研究中，诊断为 SJS/TEN 且随访至少 3 个月的患者被分为两组：接受全身 CsA 的患者和未接受全身 CsA 的患者。比较两组最终随访时的最佳矫正视力（BCVA）和慢性眼表并发症评分（COCS）。结果患者的中位年龄和随访时间分别为29岁（范围1.5~71岁）和16.8个月（范围3.67~91.58个月）。与未接受全身 CsA 的患者相比，接受全身 CsA 的患者的 BCVA、COCS、睑板腺功能障碍、角膜缘干细胞缺乏以及对粘膜移植和巩膜镜的需求没有显着差异。结论 在这一小群 SJS/TEN 患者中，我们发现使用全身 CsA 作为初始治疗的一部分与慢性眼部并发症之间没有关联。